wet AMD

Kodiak's stock doubles with win for resurrected eye disease drug

Two of Kodiak's candidates matched aflibercept in a phase 3 trial, positioning the biotech to seek approval of one of the eye disease assets this year.

Nick Paul Taylor Sep 28, 2026 8:37am

Lilly buys cash-strapped Adverum for eye disease gene therapy

Oct 24, 2025 9:25am

RemeGen sells Asia rights to VEGF/FGF eye drug in $180M deal

Aug 19, 2025 7:18am

4DMT lays off 25% of workforce while phase 3 timeline ramps up

Jul 3, 2025 4:52am

Opthea scraps wet AMD program after eye drug loses to Lucentis

Mar 31, 2025 6:55am

Opthea's eye disease drug defeated by Eylea in phase 3

Mar 24, 2025 5:24am